摘要
Targeted molecular therapy has been an elusive goal in the treatment of neo-plastic diseases. While chemotherapy has improved the outcome of many cancers, a non-selective cytotoxic approach invariably causes damage to normal cells, resulting in side effects and limiting treatment efficacy. This is evident in the evolution of treatment for castration-resistant prostate cancer （CRPC）. For instance, while mitoxantrone,
Targeted molecular therapy has been an elusive goal in the treatment of neo-plastic diseases. While chemotherapy has improved the outcome of many cancers, a non-selective cytotoxic approach invariably causes damage to normal cells, resulting in side effects and limiting treatment efficacy. This is evident in the evolution of treatment for castration-resistant prostate cancer （CRPC）. For instance, while mitoxantrone,
